RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis

Trends in Endocrinology and Metabolism

Volumn 22, Issue 5, 2011, Pages 188-194

  Schramek, Daniel ^a   Sigl, Verena ^a   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SEX HORMONE;

BONE REMODELING; BREAST CANCER; CARCINOGENESIS; METASTASIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE NEOPLASMS; BONE REMODELING; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENE EXPRESSION REGULATION; GONADAL STEROID HORMONES; HUMANS; LACTATION; NEOPLASM METASTASIS; PREGNANCY; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 79955476478     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2011.02.007     Document Type: Review

References (72)

1. Simonet W.S., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
2. Tsuda E., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997, 234:137-142.
3. Yasuda H., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3597-3602.
4. Lacey D.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
5. Wong B.R., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 1997, 272:25190-25194.
6. Anderson D.M., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
7. Nakagawa N., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 1998, 253:395-400.
8. Wong B.R., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 1997, 186:2075-2080.
9. Williamson E., et al. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. J. Immunol. 2002, 169:3606-3612.
10. Josien R., et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 1999, 162:2562-2568.
11. Fata J.E., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
12. Gonzalez-Suarez E., et al. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol. Cell. Biol. 2007, 27:1442-1454.
13. Joshi P.A., et al. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
14. Asselin-Labat M.L., et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802.
15. Schramek D., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
16. Gonzalez-Suarez E., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
17. Wei T., et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553.
18. Leibbrandt A., Penninger J.M. RANK/RANKL: regulators of immune responses and bone physiology. Ann. N.Y. Acad. Sci. 2008, 1143:123-150.
19. Wada T., et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 2006, 12:17-25.
20. Dougall W.C., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 13:2412-2424.
21. Kong Y.Y., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
22. Bucay N., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
23. Mizuno A., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247:610-615.
24. Hughes A.E., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 2000, 24:45-48.
25. Guerrini M.M., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 2008, 83:64-76.
26. Whyte M.P., et al. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 2002, 347:175-184.
27. Cummings S.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 2009, 361:756-765.
28. Smith M.R., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 2009, 361:745-755.
29. Hofbauer L.C., et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
30. Hikosaka Y., et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 2008, 29:438-450.
31. Akiyama T., et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008, 29:423-437.
32. Kong Y.Y., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
33. Hanada R., et al. Central control of fever and female body temperature by RANKL/RANK. Nature 2009, 462:505-509.
34. Mulac-Jericevic B., et al. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:9744-9749.
35. Srivastava S., et al. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J. Biol. Chem. 2003, 278:46171-46178.
36. Fernandez-Valdivia R., et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev. Biol. 2009, 328:127-139.
37. Liu X., et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11:179-186.
38. Cao Y., et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001, 107:763-775.
39. Brisken C., et al. Prolactin controls mammary gland development via direct and indirect mechanisms. Dev. Biol. 1999, 210:96-106.
40. Beleut M., et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2989-2994.
41. Mukherjee A., et al. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor. FASEB J. 2010, 24:4408-4419.
42. Cao Y., et al. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15852-15857.
43. Kim N.S., et al. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol. Cell. Biol. 2006, 26:1002-1013.
44. Yokota Y., et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999, 397:702-706.
45. Shackleton M., et al. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
46. Stingl J., et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
47. Asselin-Labat M.L., et al. Delineating the epithelial hierarchy in the mouse mammary gland. Cold Spring Harb. Symp. Quant. Biol. 2008, 73:469-478.
48. Wagner K.U., et al. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res. 2001, 10:545-553.
49. Jemal A., et al. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
50. Ferlay J., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007, 18:581-592.
51. Paget S. The distribution of secondary growths in cancer of the breast. Reproduced from The Lancet, 1889. Cancer Metastasis Rev. 1989, 8:98-101.
52. Jones D.H., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
53. Morony S., et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 2001, 61:4432-4436.
54. Canon J.R., et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 2008, 25:119-129.
55. Huang L., et al. Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases. J. Clin. Pathol. 2002, 55:877-878.
56. Van Poznak C., et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J. Clin. Pathol. 2006, 59:56-63.
57. Park H.R., et al. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J. Korean Med. Sci. 2003, 18:541-546.
58. Miller R.E., et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol. Cancer Ther. 2008, 7:2160-2169.
59. Ignatoski K.M., et al. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 2008, 68:820-829.
60. Jones D.H., et al. Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. 2002, 61(Suppl. 2):ii32-39.
61. Grimaud E., et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 2003, 163:2021-2031.
62. Bhatia P., et al. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin. Cancer Res. 2005, 11:162-165.
63. Cross S.S., et al. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J. Clin. Pathol. 2006, 59:716-720.
64. Reinholz M.M., et al. Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res. Treat. 2002, 74:255-269.
65. Santoro N., et al. Characterization of reproductive hormonal dynamics in the perimenopause. J. Clin. Endocrinol. Metab. 1996, 81:1495-1501.
66. Rossouw J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
67. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
68. Beral V., et al. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005, 365:1543-1551.
69. Aldaz C.M., et al. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 1996, 17:2069-2072.
70. McTiernan A., et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J. Natl. Cancer Inst. 2005, 97:1366-1376.
71. Schett G., et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004, 291:1108-1113.
72. Jorgensen L., et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. Osteoporos. Int. 2010, 21:931-938.